This new indication - the fifth FDA approval for CYRAMZA in an advanced or metastatic cancer - is for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL)
Approximately forty percent of all patients with advanced HCC are AFP-High and are a patient population that can have more aggressive disease and a poorer prognosis
Concurrent with this approval, the FDA has also removed the boxed warning from the CYRAMZA labeling
PR Newswire
INDIANAPOLIS, May 13, 2019
